Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100698 · ClinicalTrials.gov registry record · NA
Physiologic Growth Hormone Effects in HIV Lipodystrophy
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00100698: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00100698 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100698, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will investigate long-term, low-dose growth hormone administration in HIV-infected patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We hypothesize that low-dose growth hormone will reduce visceral fat. Secondary endpoints will include measures of insulin-like growth factor-1 (IGF-1), glucose homeostasis, lipids, blood pressure,bone density, cardiovascular risk and safety parameters.
Interventions
- DRUG placebo
- DRUG recombinant human growth hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100698
The ClinicalTrials.gov registry entry for NCT00100698 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00100698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100698 about?
NCT00100698 is a clinical study titled "Physiologic Growth Hormone Effects in HIV Lipodystrophy". This study will investigate long-term, low-dose growth hormone administration in HIV-infected patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We hypothesize that low-dose growth hormone will reduce visceral fat. Secondary endpoints will include measures of insul...
What is the current status of trial NCT00100698?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2004-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00100698?
The interventions under investigation include: placebo (DRUG), recombinant human growth hormone (DRUG).
Who is sponsoring clinical trial NCT00100698?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.